Haleon PLC has consistently executed its
Share Buyback Program, purchasing a total of 354,000 shares. Meanwhile, the company's total issued shares amount to 8.96 billion, each with voting rights. An organic reduction in revenue foreshadowed a drop in
Haleon's stock price. However, spurred by a recent share buyback transaction that cancelled over 1.3 million shares, and strong earning growth, the company has reportedly fostered a robust financial position.
Berenberg reduced its target for Haleon's stocks to $13.41 due to slower growth expectations. Amidst this, Haleon has formed a partnership with
Brightseed and hosted the inaugural
DENTAL 20 International Symposium with the Indian Dental Association. Share awards have also been granted to senior executives as per incentive plans. Interestingly,
Pfizer sold its final Haleon shares for $3.2B, ending its stake in the consumer healthcare giant. Haleon's earnings weren't as high as expected, sparking a strategic rebalance. Nonetheless, Haleon continues to optimize its capital structure and enhance shareholder value.
Haleon Stocks News Analytics from Wed, 15 Jan 2025 08:00:00 GMT to Sat, 06 Sep 2025 15:56:55 GMT -
Rating -1
- Innovation 5
- Information 7
- Rumor -5
